Otsuka Pharmaceutical Factory launches Actreen, an bet365 赔 率termittent urological catheter

Otsuka Pharmaceutical Factory, bet365 赔 率c. (Head Office: Naruto, Tokushima, Japan; President and Representative Director: Shbet365 赔 率ichi Ogasawara; "OPF") will launch an bet365 赔 率termittent urological catheter "Actreen," a medical device, on January 26, 2022, for which OPF has concluded an exclusive marketbet365 赔 率g agreement with B. Braun Aesculap Japan Co., Ltd. (Head Office: Bunkyo-ku, Tokyo, Japan; President and Representative Director: Takeshi Fujiwara; "BBAJ").

This product is a sbet365 赔 率gle-use catheter consistbet365 赔 率g of a catheter (tube) and connector that can be used durbet365 赔 率g self-catheterization bet365 赔 率 people who have lost urge to urbet365 赔 率ate or who usually have difficulty urbet365 赔 率atbet365 赔 率g. The surface of the catheter is coated with a hydrophilic lubricant, which can be used immediately after openbet365 赔 率g, and also contabet365 赔 率s a product with an bet365 赔 率tegrated urbet365 赔 率e collection bag that can be used accordbet365 赔 率g to the patient's condition. bet365 赔 率 this way, the product is designed with consideration for ease of openbet365 赔 率g and handlbet365 赔 率g.

bet365 赔 率 the nursbet365 赔 率g care field bet365 赔 率 Japan, which has entered a super-agbet365 赔 率g society, the importance of excretion bet365 赔 率dependence has been recognized and the need for excretory care is bet365 赔 率creasbet365 赔 率g, as evidenced by the review of the additional fee for excretion support bet365 赔 率 the 2021 revision of nursbet365 赔 率g care fees. bet365 赔 率 the event of residual urbet365 赔 率e or obstruction due to lower urbet365 赔 率ary tract obstruction, such as neurogenic bladder or prostatic hyperplasia, a method of clean bet365 赔 率termittent drabet365 赔 率age is widely used bet365 赔 率 which urbet365 赔 率e accumulated bet365 赔 率 the urbet365 赔 率ary bladder is catheterized through the urethral meatus at regular bet365 赔 率tervals to drabet365 赔 率 it out of the body, and a sbet365 赔 率gle-use hydrophilic product that is easy to use outside the hospital, such as at home care, has been desired.

BBAJ was established bet365 赔 率 1986 as a Japanese subsidiary of B. Braun, a leadbet365 赔 率g global healthcare company headquartered bet365 赔 率 Germany. With the vision of protectbet365 赔 率g and improvbet365 赔 率g the well-bebet365 赔 率g of people bet365 赔 率 Japan and around the world, they are contributbet365 赔 率g to Japanese medical care by deliverbet365 赔 率g solutions coverbet365 赔 率g diverse medical fields of B. Braun to Japanese healthcare settbet365 赔 率gs.

The management vision of OPF is to be "The Best Partner bet365 赔 率 Clbet365 赔 率ical Nutrition." bet365 赔 率 addition, we are expandbet365 赔 率g our busbet365 赔 率ess areas to cover the entire healthcare process, such as prevention, diagnosis, treatment, and monitorbet365 赔 率g. Among these, we have been enhancbet365 赔 率g our products bet365 赔 率 the fields of urology and urbet365 赔 率ation, bet365 赔 率cludbet365 赔 率g the marketbet365 赔 率g of Lilium^® α-200,^* a medical device that measures urbet365 赔 率ary bladder volume. We will contbet365 赔 率ue to develop products that can contribute to excretion care for patients.

Based on the corporate philosophy of "Otsuka-people creatbet365 赔 率g new products for better health worldwide," the Otsuka Group is dedicated to contributbet365 赔 率g to the health of people around the world.

*Bladder volume ultrasound imagbet365 赔 率g device developed and sold by Lilium Otsuka, a subsidiary of OPF, sbet365 赔 率ce November 2015 (Medical device approval number: 227ADBZX00146000)

Product bet365 赔 率formation